UNLABELLED: Paediatric inflammatory bowel disease (IBD), especially Crohn's disease (CD), is commonly associated with poor skeletal health, related to the direct effects of chronic inflammation, prolonged use of glucocorticoid (GC), poor nutrition, delayed puberty and low muscle mass. Low bone mineral density is commonly reported, although the prevalence of long bone fractures may not be increased in these patients. Emerging evidence however suggests that there may be an increased risk of vertebral fractures (VFs) in this group. VFs presenting at diagnosis of paediatric CD, prior to any GC exposure, have been reported, highlighting the deleterious effect of inflammation on skeletal health. This paper reviews the published literature on pathophysiology of skeletal morbidity and fractures in paediatric IBD, illustrated with a new case report of multiple VFs in a prepubertal girl with CD, soon after diagnosis, who received minimal amounts of oral GC. Optimising control of disease, addressing vitamin D deficiency, encouraging physical activity and ensuring normal growth and pubertal progression are paramount to management of bone health in these patients. Despite the lack of evidence, there may be a place for bisphosphonate treatment, especially in the presence of symptomatic pathological fractures, but this requires close monitoring by clinicians with expertise in paediatric bone health. CONCLUSION: Chronic inflammation mediated by pro-inflammatory cytokines may have adverse effects on skeletal health in paediatric patients with IBD. The risk of vertebral fractures may be increased, even without exposure to glucocorticoid. Clinical monitoring of these patients requires careful attention to the various factors that impact on bone health.
UNLABELLED: Paediatric inflammatory bowel disease (IBD), especially Crohn's disease (CD), is commonly associated with poor skeletal health, related to the direct effects of chronic inflammation, prolonged use of glucocorticoid (GC), poor nutrition, delayed puberty and low muscle mass. Low bone mineral density is commonly reported, although the prevalence of long bone fractures may not be increased in these patients. Emerging evidence however suggests that there may be an increased risk of vertebral fractures (VFs) in this group. VFs presenting at diagnosis of paediatric CD, prior to any GC exposure, have been reported, highlighting the deleterious effect of inflammation on skeletal health. This paper reviews the published literature on pathophysiology of skeletal morbidity and fractures in paediatric IBD, illustrated with a new case report of multiple VFs in a prepubertal girl with CD, soon after diagnosis, who received minimal amounts of oral GC. Optimising control of disease, addressing vitamin D deficiency, encouraging physical activity and ensuring normal growth and pubertal progression are paramount to management of bone health in these patients. Despite the lack of evidence, there may be a place for bisphosphonate treatment, especially in the presence of symptomatic pathological fractures, but this requires close monitoring by clinicians with expertise in paediatric bone health. CONCLUSION:Chronic inflammation mediated by pro-inflammatory cytokines may have adverse effects on skeletal health in paediatric patients with IBD. The risk of vertebral fractures may be increased, even without exposure to glucocorticoid. Clinical monitoring of these patients requires careful attention to the various factors that impact on bone health.
Authors: Anniek M Terpstra; Heidi J Kalkwarf; Justine Shults; Babette S Zemel; Rachel J Wetzsteon; Bethany J Foster; C Frederic Strife; Debbie L Foerster; Mary B Leonard Journal: J Am Soc Nephrol Date: 2012-01-26 Impact factor: 10.121
Authors: Francisco A Sylvester; Nancy Wyzga; Jeffrey S Hyams; Patricia M Davis; Trudy Lerer; Katherine Vance; Gillian Hawker; Anne M Griffiths Journal: Inflamm Bowel Dis Date: 2007-01 Impact factor: 5.325
Authors: Rebecca J Hill; Denise S K Brookes; Peter J Lewindon; Geoffrey D Withers; Looi C Ee; Frances L Connor; Geoffrey J Cleghorn; Peter S W Davies Journal: J Pediatr Gastroenterol Nutr Date: 2009-05 Impact factor: 2.839
Authors: S C Wong; A Smyth; E McNeill; P J Galloway; K Hassan; P McGrogan; S F Ahmed Journal: Clin Endocrinol (Oxf) Date: 2010-02-23 Impact factor: 3.478
Authors: L M Ward; J Ma; F Rauch; E I Benchimol; J Hay; M B Leonard; M A Matzinger; N Shenouda; B Lentle; H Cosgrove; M Scharke; V N Konji; D R Mack Journal: Osteoporos Int Date: 2017-08-08 Impact factor: 4.507
Authors: Karolina Śledzińska; Piotr Landowski; Michał A Żmijewski; Barbara Kamińska; Konrad Kowalski; Anna Liberek Journal: Nutrients Date: 2022-02-28 Impact factor: 5.717
Authors: B J Hurtgen; C L Ward; K Garg; B E Pollot; S M Goldman; T O McKinley; J C Wenke; B T Corona Journal: J Musculoskelet Neuronal Interact Date: 2016-06-01 Impact factor: 2.041
Authors: Ross Dobie; Vicky E MacRae; Chloe Pass; Elspeth M Milne; S Faisal Ahmed; Colin Farquharson Journal: Dis Model Mech Date: 2018-01-17 Impact factor: 5.758
Authors: S Ghatan; A Costantini; R Li; C De Bruin; N M Appelman-Dijkstra; E M Winter; L Oei; Carolina Medina-Gomez Journal: Curr Osteoporos Rep Date: 2021-05-04 Impact factor: 5.096